within Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AC19_Olodaterol;

model Olodaterol
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 0.00024222222222222223,
    adminDuration = 600,
    adminMass = 5 / 1000000,
    adminCount = 1,
    Vd = 1.11,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.32,
    k12 = 8.194444444444444e-05,
    k21 = 8.194444444444444e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Olodaterol</td></tr><tr><td>ATC code:</td><td>R03AC19</td></tr><td>route:</td><td>inhalation</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>5</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1110</td><td>L</td></tr>
    <tr><td>clearance:</td><td>872</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Olodaterol is a long-acting beta2-adrenergic agonist (LABA) used for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). It is inhaled, offering bronchodilation lasting 24 hours, and is approved for use in many countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult subjects after inhaled administration of olodaterol; parameters represent typical population values following repeat dosing of 5 micrograms once daily via the Respimat inhaler.</p><h4>References</h4><ol><li><p>Borghardt, JM, et al., &amp; Kloft, C (2016). Investigating pulmonary and systemic pharmacokinetics of inhaled olodaterol in healthy volunteers using a population pharmacokinetic approach. <i>British journal of clinical pharmacology</i> 81(3) 538–552. DOI:<a href=\"https://doi.org/10.1111/bcp.12780\">10.1111/bcp.12780</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26348533/\">https://pubmed.ncbi.nlm.nih.gov/26348533</a></p></li><li><p>Borghardt, JM, et al., &amp; Kloft, C (2016). Model-based evaluation of pulmonary pharmacokinetics in asthmatic and COPD patients after oral olodaterol inhalation. <i>British journal of clinical pharmacology</i> 82(3) 739–753. DOI:<a href=\"https://doi.org/10.1111/bcp.12999\">10.1111/bcp.12999</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27145733/\">https://pubmed.ncbi.nlm.nih.gov/27145733</a></p></li><li><p>Deeks, ED (2015). Olodaterol: a review of its use in chronic obstructive pulmonary disease. <i>Drugs</i> 75(6) 665–673. DOI:<a href=\"https://doi.org/10.1007/s40265-015-0371-4\">10.1007/s40265-015-0371-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25773742/\">https://pubmed.ncbi.nlm.nih.gov/25773742</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.R.R03AC19 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Olodaterol;
